Glyoxalase I is part of the glyoxalase system present in the cytosol of cells. The glyoxalase system catalyses the conversion of reactive, acyclic α-oxoaldehydes into the corresponding α-hydroxyacids. Glyoxalase I catalyses the isomerization of the hemithioacetal, formed spontaneously from α-oxoaldehyde and GSH, to S-2-hydroxyacylglutathione derivatives [RCOCH(OH)-SG → RCH(OH) CO-SG], and in so doing decreases the steady-state concentrations of physiological α-oxoaldehydes and associated glycation reactions. Physiological substrates of glyoxalase I are methylglyoxal, glyoxal and other acyclic α-oxoaldehydes. Human glyoxalase I is a dimeric Zn 2+ metalloenzyme of molecular mass 42 kDa. Glyoxalase I from Escherichia coli is a Ni 2+ metalloenzyme. The crystal structures of human and E. coli glyoxalase I have been determined to 1.7 and 1.5 Å resolution. The Zn 2+ site comprises two structurally equivalent residues from each domain -Gln-33A, Glu-99A, His-126B, Glu-172B and two water molecules. The Ni 2+ binding site comprises His-5A, Glu-56A, His-74B, Glu-122B and two water molecules. The catalytic reaction involves base-catalysed shielded-proton transfer from C-1 to C-2 of the hemithioacetal to form an ene-diol intermediate and rapid ketonization to the thioester product. R-and S-enantiomers of the hemithioacetal are bound in the active site, displacing the water molecules in the metal ion primary co-ordination shell. It has been proposed that Glu-172 is the catalytic base for the S-substrate enantiomer and Glu-99 the catalytic base for the R-substrate enantiomer; Glu-172 then reprotonates the ene-diol stereospecifically to form the R-2-hydroxyacylglutathione product. By analogy with the human enzyme, Glu-56 and Glu-122 may be the bases involved in the catalytic mechanism of E. coli glyoxalase I. The suppression of α-oxoaldehyde-mediated glycation by glyoxalase I is particularly important in diabetes and uraemia, where α-oxoaldehyde concentrations are increased. Decreased glyoxalase I activity in situ due to the aging process and oxidative stress results in increased glycation and tissue damage. Inhibition of glyoxalase I pharmacologically with specific inhibitors leads to the accumulation of α-oxoaldehydes to cytotoxic levels; cell-permeable glyoxalase I inhibitors are antitumour and antimalarial agents. Glyoxalase I has a critical role in the prevention of glycation reactions mediated by methylglyoxal, glyoxal and other α-oxoaldehydes in vivo.
The glyoxalase system
Glyoxalase I (EC 4.4.1.5) is part of the glyoxalase system present in the cytosol of all cells. The glyoxalase system catalyses the conversion of reactive, acyclic α-oxoaldehydes into the corresponding α-hydroxyacids. It is composed of two enzymes, glyoxalase I and glyoxalase II (EC 3.1.2.6), and a catalytic amount of GSH. Glyoxalase I catalyses the isomerization of the hemithioacetal, formed spontaneously from α-oxoaldehyde (RCOCHO) and GSH, into
S-2-hydroxyacylglutathione derivatives
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[RCH(OH)CO-SG]: RCOCHO + GSH ↔ RCOCH(OH)-SG → RCH(OH)CO-SG
For the methylglyoxal-glutathione hemithioacetal and human glyoxalase I, the K m is 71-130 µM and the k cat is (7-11) × 10 4 min −1 . Glyoxalase II catalyses the conversion of S-2-hydroxyacylglutathione derivatives into α-hydroxyacids and re-forms GSH consumed in the glyoxalase I-catalysed reaction step. The major physiological substrate for glyoxalase I is methylglyoxal, and this accumulates markedly when glyoxalase I is inhibited in situ by cell-permeable glyoxalase I inhibitors and by depletion of GSH [1] [2] [3] . Methylglyoxal is formed mainly by the degradation of triose phosphates, and also by the metabolism of ketone bodies, threonine degradation and the fragmentation of glycated proteins. Other substrates are glyoxal (formed by lipid peroxidation and the fragmentation of glycated proteins), hydroypyruvaldehyde (HOCH 2 COCHO) and 4,5-doxovalerate (H-COCOCH 2 CH 2 CO 2 H) [1, 4] . Glyoxalase I activity prevents the accumulation of these reactive α-oxoaldehydes and thereby suppresses α-oxoaldehyde-mediated glycation reactions [5] . It is, therefore, a key enzyme of the antiglycation defence.
Molecular properties of glyoxalase I
Glyoxalase I activity is present in all human tissues. Specific activities of fetal tissues are approx. 3 times higher than those of corresponding adult tissues. There is approx. 0.2 µg of glyoxalase I per mg of protein in human tissues and blood cells. Human glyoxalase I is a dimer, expressed at a diallelic genetic locus, GLO, which encodes two similar subunits in heterozygotes; the three alloenzymes are designated GLO 1-1, GLO 1-2 and GLO 2-2. All alloenzymes have molecular mass of 46 kDa (gel filtration) or 42 kDa (sequence), and pI values of 4.8-5.1; however, they have distinctive charge densities and/or molecular shapes and are resolved by ion exchange chromatography and non-denaturing gel electrophoresis. Each subunit contains one Zn 2+ ion [1] . Surprisingly, glyoxalase I from Escherichia coli is a Ni 2+ metalloenzyme [6] .
To 
Structure and catalytic mechanism of glyoxalase I
The translation product of the human glyoxalase I gene contains 184 amino acids. The N-terminal Met is removed in post-translational processing and the N-terminal Ala is blocked by an as-yet-unknown modification. There are at least four possible phosphorylation sites. The structure of human glyoxalase I in complex with S-benzylglutathione was determined to 2.2 Å resolution [7] (Figure 1a ). Each monomer consists of two structurally equivalent domains. The active site is situated in the dimer interface, with the inhibitor and essential Zn 2+ ion interacting with side chains from both subunits. The zinc binding site comprises two structurally equivalent residues from each domain -Gln-33A, Glu-99A, His-126B, Glu-172B and two water molecules in octahedral co-ordination. The competitive inhibitors S-p-bromobenzylglutathione and S-(p-nitrobenzoxycarbonyl)glutathione were bound in the second co-ordination shell of Zn 2+ in extended conformation, whereas the transition-state analogue inhibitor S-[N-hydroxy-N-(p-iodophenyl)carbamoyl]glutathione was bound directly to the Zn 2+ ion by its carbamoyl oxygens in a cis conformation. The carboxylate group of the γ-Glu residue formed a salt bridge link to the guanidino group of Arg-37A and the amide group of Asn-103A; Arg-122B was within hydrogen bonding distance of the γ-Glu residue. Gly was not bound [7, 8] .
Glyoxalase I of Escherichia coli is composed of two identical 135-amino-acid subunits. The crystal structure of the Ni 2+ -bound enzyme has been determined to 1.5 Å resolution. Each subunit consists of two domains, residues 3-60 and 72-126, that are linked by an intervening 12-residue segment. Each domain consists of a βαββ motif. The Ni 2+ ion is coordinated by His-5A, Glu-56A, His-74B, Glu-122B and two water molecules in an octahedral co-ordination (Figure 1b) .
The mechanism proposed for the glyoxalase I reaction involves base-catalysed shielded-proton transfer from C-1 to C-2 of the hemithioacetal, bound in the active site, to form an ene-diol intermediate, and rapid ketonization to the thioester product (Figure 1c ). Both R-and S-forms of the hemithioacetal are bound in the active site of glyoxalase I and are therein deprotonated; the subsequent reprotonation of the putative ene-diol intermediate occurs stereospecifically to form the R-2-hydroxyacylglutathione derivative. It has been proposed that Glu-172 is the catalytic base for the S-substrate enantiomer and Glu-99 the catalytic base for the R-substrate enantiomer. Both reaction mechanisms form a cis-ene-diol intermediate co-ordinated directly to the Zn 2+ ion: this is deprotonated to a cis-ene-diolate by Glu-172, which then reprotonates C-2 stereospecifically to form the R-2-hydroxyacylglutathione product [9] (Figure 1c) . S-Glycolylglutathione, S-D-lactoylglutathione and S-Lglyceroylglutathione are formed from glyoxal, methylglyoxal and hydroypyruvaldehyde respectively by glyoxalase I, and hydrolysed to glycolate, D-lactate and L-glycerate respectively by glyoxalase II [10] . By analogy with the human enzyme, Glu-56 and Glu-122 may be the bases involved in the catalytic mechanism [11] .
Genetics and polymorphism
There are three phenotypes of human glyoxalase I, GLO 1-1, GLO 1-2 and GLO 2-2, representing the homozygous and heterozygous expression of a diallelic gene, GLO 1 and GLO 2 , at an autosomal locus; the GLO 2 allele is the ancestral allele, with the GLO 1 allele arising by mutation. GLO alleles are inherited in a simple co-dominant manner, with characteristic phenotypic expression present in all tissues. The GLO locus is on chromosome 6, between the centromere and HLA-DR. The population genetics of GLO 1 allele frequency show that this frequency is highest in native tribes in Alaska, and decreases geographically South and East to Europe and South America, through Africa, the Middle East and India, to the very low GLO 1 allele frequencies of the Far East and Oceania [12] . The allele expression products differ in amino acid sequence only at position 111: in subunit GloI-A there is an alanine residue, and in subunit GloI-E there is a glutamic acid residue [13] . The gene promoter contains an insulin response element and a metal response element [14] . There was a phenotypic disturbance of GLO in Type I diabetic patients with and without chronic microvascular complications (retinopathy and neuropathy).
Diabetic patients without complications showed a significantly increased frequency of GLO 1-1 homozygotes [15] .
Role of glyoxalase I in the anti-glycation defence
The formation of methylglyoxal is an intrinsic feature of the Embden-Meyerhof pathway; a corollary to the presence of triose phosphate intermediates in glycolysis. It is minimized by maintaining low concentrations of triose phosphates at steady state and capping of the active site in triose phosphate isomerase. Consequently, the formation of methylglyoxal accounts for only approx. 0.1-0.4% of glucotriose flux. Methylglyoxal has high reactivity in glycation reactions The glyoxalase system is an efficient enzymatic detoxification system suppressing the formation of methylglyoxaland glyoxal-derived AGEs. Recent quantitative analysis of methylglyoxal-derived glycation adducts of cellular and extracellular proteins indicates that 0.1-2% of total cellular arginine is modified by methylglyoxal -the highest estimate being in human lens proteins of elderly subjects with low glyoxalase I activity [18, 19] . A patient with end-stage renal disease and unusually low glyoxalase I activity also had high levels of AGEs and a susceptibility to recurrent events of macrovascular disease when conventional risk factors were controlled [20] . Convincing experimental evidence that glyoxalase I suppresses the formation of AGEs came from studies of endothelial cells in normoglycaemic and hyperglycaemic culture. Hyperglycaemia induced increases in the concentrations of methylglyoxal, D-lactate and cellular protein AGEs. Overexpression of glyoxalase I prevented totally the increase in methylglyoxal and cellular protein AGEs, and increased the concentration of D-lactate. This indicated that glyoxalase I has a critical role in suppressing the formation of protein AGEs [5] (Figures 2b-2e) .
Glyoxalase I is a GSH-dependent enzyme. Under physiological conditions in situ, the rate of fragmentation of hemithioacetal to GSH and methylglyoxal is of the order of 10 3 times faster than the rate of isomerization by glyoxalase I. Therefore, there is a rapid pre-equilibrium of GSH and methylglyoxal with hemithioacetal, and the activity of glyoxalase I in situ is proportional to the cellular concentration of GSH. Experimental depletion of GSH, by oxidative or non-oxidative mechanisms [exposure to cytotoxic levels of hydrogen peroxide or the glutathione transferase substrate CDNB (1-chloro-2,4-dinitrobenzene)], induced marked accumulation of methylglyoxal and a much smaller increase in glyoxal, and induced cytotoxicity. Scavenging of α-oxoaldehydes by aminoguanidine prevented the accumulation of α-oxoaldehydes and cytotoxicity. This indicates that methylglyoxal accumulates markedly in oxidative stress and may mediate oxidant-induced cytotoxicity [2] (Figures 3a  and 3b) .
The cytotoxicity associated with the accumulation of methylglyoxal and other glyoxalase I substrates should be avoided under normal physiological states. Hence the function of glyoxalase I is the detoxification of α-oxoaldehydes as part of the enzymatic defence against glycation. In certain disease states, such as cancer and microbial infections, we may wish to induce cytotoxicity of tumour cells and microbial organisms pharmacologically. A cell-permeable glyoxalase I inhibitor achieves this.
SpBrBzGSH (S-p-bromobenzylglutathione) is a potent inhibitor of human glyoxalase I (K i 83 nM). Diesterification of SpBrBzGSH stabilizes this GSH conjugate to extracellular degradation by γ-glutamyl transpeptidase and makes it cell permeable. Inside cells, SpBrBzGSH diesters are de-esterified and glyoxalase I is inhibited. SpBrBzGSHCp 2 (SpBrBzGSH cyclopentyl diester) was a potent antitumour agent in vitro and had antitumour activity in vivo [3] . More recent studies have shown overexpression of glyoxalase I associated with multidrug resistance in cancer chemotherapy, where potent antitumour activity was achieved with SpBrBzGSHCp 2 (Figure 3c and discussed elsewhere in this colloquium [17] ). SpBrBzGSHEt 2 (SpBrBzGSH ethyl diester) had potent antimalarial activity against the red blood cell stage of Plasmodium falciparum (Figure 3d ). This stage of the malarial parasite has only anaerobic glycolysis and an associated high flux of methylglyoxal formation. It is, therefore, particularly sensitive to pharmacological inhibition of glyoxalase I, with associated accumulation of methylglyoxal to cytotoxic levels [21] .
Conclusions
There is established and further emerging evidence that the physiological substrates of glyoxalase I are potent glycating agents of proteins, nucleotides and basic phospholipids, and that these glycation processes contribute to cell and tissue damage in vivo. This is particularly marked in diabetes and uraemia, where α-oxoaldehyde concentrations are increased [22, 23] . By the efficient metabolism of α-oxoaldehydes, glyoxalase I provides an enzymatic defence against α-oxoaldehyde-mediated glycation. Decreasing glyoxalase I activity in situ due to the aging process and oxidative stress increases glycation and tissue damage. The glyoxalase I defence against glycation appears to be a factor associated with risk of developing vascular complications of diabetes and uraemia. Surprisingly, glyoxalase I activity is also linked with multidrug resistance in cancer chemotherapy, suggesting a role of methylglyoxal-induced apoptosis in the mechanism of action of some antitumour drugs.
